FI3698790T3 - Menetelmiä epänormaalin solukasvun hoitamiseksi - Google Patents

Menetelmiä epänormaalin solukasvun hoitamiseksi Download PDF

Info

Publication number
FI3698790T3
FI3698790T3 FIEP20154659.5T FI20154659T FI3698790T3 FI 3698790 T3 FI3698790 T3 FI 3698790T3 FI 20154659 T FI20154659 T FI 20154659T FI 3698790 T3 FI3698790 T3 FI 3698790T3
Authority
FI
Finland
Prior art keywords
cancer
administered
inhibitor
use according
fak inhibitor
Prior art date
Application number
FIEP20154659.5T
Other languages
English (en)
Finnish (fi)
Inventor
Qunli Xu
Jonathan A Pachter
Winnie Tam
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Application granted granted Critical
Publication of FI3698790T3 publication Critical patent/FI3698790T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
FIEP20154659.5T 2014-02-07 2015-02-06 Menetelmiä epänormaalin solukasvun hoitamiseksi FI3698790T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461937253P 2014-02-07 2014-02-07

Publications (1)

Publication Number Publication Date
FI3698790T3 true FI3698790T3 (fi) 2023-06-06

Family

ID=53778481

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20154659.5T FI3698790T3 (fi) 2014-02-07 2015-02-06 Menetelmiä epänormaalin solukasvun hoitamiseksi

Country Status (7)

Country Link
US (4) US9962385B2 (enExample)
EP (2) EP3698790B1 (enExample)
JP (3) JP2017505321A (enExample)
DK (2) DK3698790T3 (enExample)
ES (2) ES2779975T3 (enExample)
FI (1) FI3698790T3 (enExample)
WO (1) WO2015120289A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115708827A (zh) * 2014-01-09 2023-02-24 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法
ES2987376T3 (es) 2015-06-29 2024-11-14 Verastem Inc Composiciones terapéuticas, combinaciones y métodos de uso
WO2018148666A1 (en) * 2017-02-13 2018-08-16 University Of Pittsburgh-Of The Commonwealth Systems Of Higher Education Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
IL257225A (en) * 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2020191105A2 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
WO2020236620A1 (en) * 2019-05-17 2020-11-26 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies
MX2022000082A (es) * 2019-06-21 2022-06-16 Pattern Computer Inc Composiciones terapeuticas y metodos para tratar canceres.
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US20230145356A1 (en) * 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
CA3163095A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
WO2021142144A1 (en) 2020-01-10 2021-07-15 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
EP4096671A4 (en) * 2020-01-31 2024-02-28 Verastem, Inc. COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
US20230079055A1 (en) 2020-02-05 2023-03-16 Inxmed (Nanjing) Co., Ltd. Combination of bi853520 with chemotherapeutic drugs
WO2022170060A1 (en) * 2021-02-05 2022-08-11 Verastem, Inc. Combination therapy for treating abnormal cell growth
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
PE20121816A1 (es) 2009-10-12 2013-01-02 Hoffmann La Roche Combinaciones de un inhibidor de pi3k y un inhibidor de mek
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
HK1202265A1 (en) 2012-06-08 2015-09-25 霍夫曼-拉罗奇有限公司 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
US20160263116A1 (en) * 2012-10-12 2016-09-15 Glaxosmithkline Llc Combinations

Also Published As

Publication number Publication date
EP3102232A4 (en) 2017-09-27
JP7289807B2 (ja) 2023-06-12
US9962385B2 (en) 2018-05-08
EP3698790A1 (en) 2020-08-26
HK1232152A1 (en) 2018-01-05
DK3102232T3 (da) 2020-04-20
US20190046531A1 (en) 2019-02-14
EP3698790B1 (en) 2023-04-05
US10406158B2 (en) 2019-09-10
US20160346282A1 (en) 2016-12-01
JP2017505321A (ja) 2017-02-16
ES2945387T3 (es) 2023-06-30
US20200147080A1 (en) 2020-05-14
JP7578643B2 (ja) 2024-11-06
WO2015120289A1 (en) 2015-08-13
JP2020079320A (ja) 2020-05-28
DK3698790T3 (da) 2023-06-19
JP2022113886A (ja) 2022-08-04
ES2779975T3 (es) 2020-08-21
US20230321097A1 (en) 2023-10-12
EP3102232A1 (en) 2016-12-14
EP3102232B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
FI3698790T3 (fi) Menetelmiä epänormaalin solukasvun hoitamiseksi
JP2017505321A5 (enExample)
ZA202309638B (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
MX372942B (es) Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[(3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer.
MX2023012060A (es) Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
NZ628078A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
ZA201607488B (en) Compounds for treating brain cancer
WO2016161361A4 (en) Compositions and methods of targeting mutant k-ras
MX2018013941A (es) Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1.
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
TW201613589A (en) Combination methods for treating cancers
Das et al. Liposomal nanostructures for drug delivery in gastrointestinal cancers
MX2018012457A (es) Terapia combinatoria con inhibidores notch y cdk4/6.
Jamieson et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
JP2016529285A5 (enExample)
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
JP2019510075A5 (enExample)
TW200512198A (en) 5-arylpyrimidines as anticancer agents
CN103476413B (zh) 组合
JPWO2019196764A5 (enExample)
WO2014115859A3 (ja) 分子標的併用腫瘍治療・予防薬
CN110354261B (zh) 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途
JP2018520164A5 (enExample)
WO2017164887A8 (en) Pulse dosing regimen and methods for treatment